Journal article icon

Journal article

Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.

Abstract:

OBJECTIVE: To assess the efficacy and safety of intravenous administration of golimumab in patients with rheumatoid arthritis (RA). METHODS: Adult patients with RA in whom disease activity was persistent despite treatment with methotrexate (MTX) at a dosage of 15-25 mg/week for > or = 4 weeks were randomized to receive intravenous infusions of placebo plus MTX or intravenous infusions of golimumab at a dose of 2 mg/kg or 4 mg/kg, with or without MTX, every 12 weeks through week 48. Patien...

Expand abstract

Actions


Access Document


Publisher copy:
10.1002/art.27348

Authors


Ritchlin, C More by this author
Mendelsohn, A More by this author
Expand authors...
Journal:
Arthritis and rheumatism
Volume:
62
Issue:
4
Pages:
917-928
Publication date:
2010-04-05
DOI:
EISSN:
1529-0131
ISSN:
0004-3591
URN:
uuid:b29e7521-a20a-4b67-bae8-1f44d7b29d9c
Source identifiers:
244205
Local pid:
pubs:244205

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP